)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
iBio
iBio (IBIO) investor relations material
iBio Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 earnings summary10 Nov, 2026
Executive summary
Advanced obesity and cardiometabolic programs; IBIO-600 completed dosing in all four planned Phase 1 SAD cohorts, and IBIO-610 generated additional preclinical body-composition data.
Revenue rose to $1.075 million, while net loss widened to $7.551 million; quarter-end cash and investments totaled $76.7 million.
Financial highlights
Revenue was $1.075 million versus $100,000 year over year, all from services provided to one collaborative partner.
R&D expense increased 87% to $6.650 million from $3.550 million; G&A rose to $2.763 million from $2.501 million.
Operating expenses were $9.413 million versus $6.051 million; operating loss was $8.338 million versus $5.951 million.
Net loss was $7.551 million versus $5.720 million; loss per share was $0.05 versus $0.11.
Net cash used in operations was $9.4 million versus $5.7 million.
Outlook and guidance
IBIO-610 first-in-human studies are targeted for H1 2027; an IND-equivalent filing was targeted by year-end 2026.
IBIO-600 interim SAD data are anticipated in Q1 2027, with multiple-ascending-dose testing expected to start in Q1 2027.
An IBIO-800 IND-equivalent filing is anticipated in 1H 2027; discovery candidates are targeted for 2H 2027.
Cash and debt investments are expected to fund operations into Q4 FY28; potential funding sources include warrant exercises, collaborations, out-licensing and securities offerings, with availability and terms uncertain.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from iBio
- Antibody pipeline targets better weight-loss quality and cardiometabolic outcomes beyond incretins.IBIO
Corporate presentation - Clinical readouts and filings advance across obesity and PH-HFpEF programs.IBIO3rd Annual Guggenheim Healthcare Innovation Conference
- Antibody pipeline targets durable fat loss, muscle preservation, and cardiometabolic disease.IBIOCorporate presentation
- Long-acting antibody pipeline targets obesity, muscle loss, and cardiometabolic disease with key data ahead.IBIOWells Fargo 21st Annual Healthcare Conference
- Board recommends approval of all proposals, including director elections and key amendments.IBIOProxy filing
- Advanced clinical pipeline and secured funding, extending cash runway into fiscal 2028.IBIOQ4 2026
- Shareholders will vote on director elections, auditor ratification, compensation, and key amendments.IBIOProxy filing
- Bispecific antibody targets PH-HFpEF with selective efficacy and safety, Q3 candidate milestone.IBIOStudy update
- Lead antibody programs show strong preclinical efficacy for muscle preservation and fat loss.IBIOStudy Update
Next iBio earnings date
38th Annual Healthcare Conference1 Dec, 2026
iBio
Next iBio earnings date
38th Annual Healthcare Conference1 Dec, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Bio iBionext, Inc., provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company offers development and manufacturing services for pharmaceuticals; laboratory research and diagnostics; protein research, engineering, and discovery; cell culture media products; pathogen detection; and bioproduction, packaging, and validation services. It sources raw materials from commercial suppliers primarily in North America. The company was founded in 1983 and is based in Westlake Village, California.